BAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION
This article was originally published in The Gray Sheet
Executive SummaryBAXTER'S NOVACOR LVAS AS ALTERNATIVE TO HEART TRANSPLANTATION underwent its first placement, in an English patient on Aug. 24. The implantation marks the first time that the left ventricular assist system will be evaluated as "a long-term treatment for end-stage heart failure," Baxter says. The study, in cooperation with Papworth Hospital NHS Trust of Cambridge University, is designed as a pilot program of four participants. Twenty-five patients ultimately will be enrolled. The LVAS was developed by Baxter's Novacor division.
You may also be interested in...
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.
Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.